DALLAS, February 1, 2015
/PRNewswire/ --
RnRMarketResearch.com adds Non Alcoholic Fatty Liver Disease
(NAFLD) Global Pipeline and Clinical Trials Review, H1, 2015
research reports to its store. These reports provide an overview of
the Non Alcoholic Fatty Liver Disease therapeutic pipeline and
clinical trials.
The report "Non Alcoholic Fatty Liver Disease (NAFLD) Global
Clinical Trials Review, H1, 2015″ provides data on the Non
Alcoholic Fatty Liver Disease (NAFLD) clinical trial scenario. Non
alcoholic fatty liver disease is a progressive complex of liver
disease which starts with fat accumulation in the liver without
excessive alcohol utilization. Non alcoholic fatty liver disease
can be divided into isolated fatty liver in which there is only
accumulation of fat and nonalcoholic steatohepatitis in which there
is fat and damage to liver cells. Several risk factors increase the
possibility of a person developing NAFLD and it's include diabetes,
excess weight and obesity, high levels of fat in the blood and
abdominal surgery.
This report provides elemental information and data relating to
the clinical trials on Non Alcoholic Fatty Liver Disease (NAFLD).
It includes an overview of the trial numbers and their recruitment
status as per the site of trial conduction across the globe.
Companies discussed in this Non Alcoholic Fatty Liver Disease
(NAFLD) Global Clinical Trials Review, H1, 2015 report include
Galmed International Ltd., AstraZeneca PLC, TCM Biotech
International Corp, Phenex Pharmaceuticals AG, PharmaKing Co.,
Ltd., Genextra S.p.a., F. Hoffmann-La Roche Ltd., Barij essence
Company, Antipodean Pharmaceuticals, Inc., Abbott Laboratories.
Order a copy on "Non Alcoholic Fatty Liver Disease (NAFLD) Global
Clinical Trials Review, H1, 2015" report @
http://www.rnrmarketresearch.com/contacts/purchase?rname=276883 .
(This is a premium report priced at US$2500 for a single user License.)
Scope of Non Alcoholic Fatty Liver Disease
(NAFLD) Global Clinical Trials Review, H1, 2015 covers: Data on
the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national
contributions in each; Clinical trial (complete and in progress)
data by phase, trial status, subjects recruited and sponsor type;
Listings of discontinued trials (suspended, withdrawn and
terminated).
The report "Non Alcoholic Fatty Liver Disease
(NAFLD) - Pipeline Review, H1 2015"
provides comprehensive information on the therapeutic development
for Non Alcoholic Fatty Liver Disease. It also reviews key players
involved in the therapeutic development for Non Alcoholic Fatty
Liver Disease (NAFLD) and special features on late-stage and
discontinued projects. The report is built using data and
information sourced from Global Markets Direct's proprietary
databases, Company/University websites, SEC filings, investor
presentations and featured press releases from company/university
sites and industry-specific third party sources, put together by
Global Markets Direct's team.
The report enhances decision making capabilities and help to
create effective counter strategies to gain competitive advantage.
It strengthens R&D pipelines by identifying new targets and
MOAs to produce first-in-class and best-in-class products.
Companies discussed in this Non Alcoholic Fatty Liver Disease
(NAFLD) - Pipeline Review, H1 2015 report include Conatus
Pharmaceuticals Inc., Daewoong Pharmaceutical Co., Ltd., Galmed
International Ltd., Kyorin Pharmaceutical Co., Ltd., Metabolic
Solutions Development Company, LLC, Novartis AG, Phenex
Pharmaceuticals AG, Raptor Pharmaceuticals Corp., TCM Biotech
International Corp, Tobira Therapeutics, Inc., Verva
Pharmaceuticals Limited, Zafgen Inc. Order a copy on "Non Alcoholic
Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2015" report @
http://www.rnrmarketresearch.com/contacts/purchase?rname=269573 .
(This is a premium report priced at US$2000 for a single user License.)
Scope of Non Alcoholic Fatty Liver Disease
(NAFLD) - Pipeline Review, H1 2015
covers: a snapshot of the global therapeutic landscape of Non
Alcoholic Fatty Liver Disease (NAFLD); reviews key pipeline
products under drug profile section which includes, product
description, MoA and R&D brief, licensing and collaboration
details & other developmental activities; reviews key players
involved in the therapeutics development for Non Alcoholic Fatty
Liver Disease (NAFLD) and enlists all their major and minor
projects; summarizes all the dormant and discontinued pipeline
projects; review of the Non Alcoholic Fatty Liver Disease (NAFLD)
products under development by companies and universities/research
institutes based on information derived from company and
industry-specific sources; Pipeline products coverage based on
various stages of development ranging from pre-registration till
discovery and undisclosed stages.
Global Markets Direct report features investigational drugs from
across globe covering over 20 therapy areas and nearly 3,000
indications. The report is built using data and information sourced
from Global Markets Direct's proprietary databases,
Company/University websites, SEC filings, investor presentations
and featured press releases from company/university sites and
industry-specific third party sources, put together by Global
Markets Direct's team. Drug profiles/records featured in the report
undergoes periodic updation following a stringent set of processes
that ensures that all the profiles are updated with the latest set
of information. Additionally, processes including live news &
deals tracking, browser based alert-box and clinical trials
registries tracking ensure that the most recent developments are
captured on a real time basis.
Reasons to Buy
- Provides strategically significant competitor information,
analysis, and insights to formulate effective R&D development
strategies
- Identify emerging players with potentially strong product
portfolio and create effective counter-strategies to gain
competitive advantage
- Develop strategic initiatives by understanding the focus areas
of leading companies
Identify and understand important and diverse types of therapeutics
under development for Non Alcoholic Fatty Liver Disease
(NAFLD)
- Plan mergers and acquisitions effectively by identifying key
players of the most promising pipeline
- Devise corrective measures for pipeline projects by
understanding Non Alcoholic Fatty Liver Disease (NAFLD) pipeline
depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects
to enhance and expand business potential and scope
Explore more reports on Pharmaceuticals industry at
http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals
.
About Us:
RnRMarketResearch.com is a database of syndicated market reports
for global and regional industries including but not limited to
life sciences, information technology & telecommunications,
consumer goods, food and beverages, energy and power, automotive
and transportation, manufacturing and construction, materials and
chemicals, public sector as well as business and financial
services. We provide 24/7 online and offline support to our
customers.
Contact:
Ritesh Tiwari
TX, Dallas North - Dominion
Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel: +1-888-391-5441
sales@rnrmarketresearch.com